Details

Autor(en) / Beteiligte

• Larrayoz, Marta
• Garcia-Barchino, Maria J
• Celay, Jon
• Etxebeste, Amaia
• Jimenez, Maddalen
• Perez, Cristina
• Ordoñez, Raquel
• Cobaleda, Cesar
• Botta, Cirino
• Fresquet, Vicente
• Roa, Sergio
• Goicoechea, Ibai
• Maia, Catarina
• Lasaga, Miren
• Chesi, Marta
• Bergsagel, P Leif
• Larrayoz, Maria J
• Calasanz, Maria J
• Campos-Sanchez, Elena
• Martinez-Cano, Jorge
• Panizo, Carlos
• Rodriguez-Otero, Paula
• Vicent, Silvestre
• Roncador, Giovanna
• Gonzalez, Patricia
• Takahashi, Satoru
• Katz, Samuel G
• Walensky, Loren D
• Ruppert, Shannon M
• Lasater, Elisabeth A
• Amann, Maria
• Lozano, Teresa
• Llopiz, Diana
• Sarobe, Pablo
• Lasarte, Juan J
• Planell, Nuria
• Gomez-Cabrero, David
• Kudryashova, Olga
• Kurilovich, Anna
• Revuelta, Maria V
• Cerchietti, Leandro
• Agirre, Xabier
• San Miguel, Jesus
• Paiva, Bruno
• Prosper, Felipe
• Martinez-Climent, Jose A

Titel

Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

Ist Teil von

• Nature medicine, 2023-03, Vol.29 (3), p.632-645

Ort / Verlag

United States: Nature Publishing Group

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• The historical lack of preclinical models reflecting the genetic heterogeneity of multiple myeloma (MM) hampers the advance of therapeutic discoveries. To circumvent this limitation, we screened mice engineered to carry eight MM lesions (NF-κB, KRAS, MYC, TP53, BCL2, cyclin D1, MMSET/NSD2 and c-MAF) combinatorially activated in B lymphocytes following T cell-driven immunization. Fifteen genetically diverse models developed bone marrow (BM) tumors fulfilling MM pathogenesis. Integrative analyses of ∼500 mice and ∼1,000 patients revealed a common MAPK-MYC genetic pathway that accelerated time to progression from precursor states across genetically heterogeneous MM. MYC-dependent time to progression conditioned immune evasion mechanisms that remodeled the BM microenvironment differently. Rapid MYC-driven progressors exhibited a high number of activated/exhausted CD8 T cells with reduced immunosuppressive regulatory T (T ) cells, while late MYC acquisition in slow progressors was associated with lower CD8 T cell infiltration and more abundant T cells. Single-cell transcriptomics and functional assays defined a high ratio of CD8 T cells versus T cells as a predictor of response to immune checkpoint blockade (ICB). In clinical series, high CD8 T/T cell ratios underlie early progression in untreated smoldering MM, and correlated with early relapse in newly diagnosed patients with MM under Len/Dex therapy. In ICB-refractory MM models, increasing CD8 T cell cytotoxicity or depleting T cells reversed immunotherapy resistance and yielded prolonged MM control. Our experimental models enable the correlation of MM genetic and immunological traits with preclinical therapy responses, which may inform the next-generation immunotherapy trials.